Insilico Medicine

📍 Boston, United States🗓 Founded 2014👥 293 employees💰 Last funded Jun 2021
Biotechnology Research🌐 Insilico.com
Website LinkedIn
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
8
Total investors
0
Early stage
3
Mid stage
5
Late stage
2014
Founded

Investors

8 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
4
China
4
Investor activity2018–2021 · investors recorded per year
20181201922020320212
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Insilico Medicine?
Insilico Medicine has 8 investors on record on gritt.io, 3 mid-stage and 5 late-stage investors.
When did Insilico Medicine last raise funding?
The most recent investment in Insilico Medicine recorded on gritt.io was in June 2021.
When was Insilico Medicine founded?
Insilico Medicine was founded in 2014.
What industry is Insilico Medicine in?
Insilico Medicine operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Insilico Medicine based?
Insilico Medicine is headquartered in Boston, United States.